Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A phase II trial of pan-HER inhibitor Poziotinib, in patients with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed regimens: The results of NOV120101-203 trial
- Authors
- Park, YH[Park, Y. H.]; Lee, KH[Lee, K-H.]; Sohn, J[Sohn, J.]; Lee, KS[Lee, K. S.]; Jung, KH[Jung, K. H.]; Kim, JH[Kim, J. H.]; Lee, KH[Lee, K. H.]; Ahn, JS[Ahn, J. S.]; Kim, TY[Kim, T-Y.]; Kim, GM[Kim, G. M.]; Park, IH[Park, I. H.]; Kim, SB[Kim, S-B.]; Kim, SH[Kim, S. H.]; Han, HS[Han, H. S.]; Im, YH[Im, Y-H.]; Ahn, JH[Ahn, J. H.]; Kim, JY[Kim, J-Y.]; Kang, J[Kang, J.]; Im, SA[Im, S-A.]
- Issue Date
- Sep-2017
- Publisher
- OXFORD UNIV PRESS
- Citation
- ANNALS OF ONCOLOGY, v.28
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 28
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.